A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
A phase 1/2 trial of pembrolizumab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Shanghai 6th People's Hospital, not yet recruiting.
Overview
A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma is a phase 1/2, randomised interventional study registered as NCT07632235 by Shanghai 6th People's Hospital, with a registry enrolment figure of 112 participants, started 2026-09-15 and due to reach its primary completion in 2029-12-31. Interventions recorded: Celecoxib + Pembrolizumab + Gemcitabine/Cisplatin, Pembrolizumab + Gemcitabine/Cisplatin. Conditions listed: Intrahepatic Cholangiocarcinoma (Icc). Gallbladder cancer is named in the registry entry: "* Other primary malignancies including extrahepatic cholangiocarcinoma, gallbladder carcinoma, or ampullary carcinoma.". Sites: China. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPerioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents and the tag gallbladder-deep-dive.
- TrialChidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents and the tag gallbladder-deep-dive.
- TrialA Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer
Shares Ampullary cancer (ampulla of Vater), Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
- TrialQL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents and the tag gallbladder-deep-dive.
- TrialAdebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents and the tag gallbladder-deep-dive.
- TrialAlternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents and the tag gallbladder-deep-dive.
- TrialAlternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
Shares Ampullary cancer (ampulla of Vater), Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
- TrialEnvafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents and the tag gallbladder-deep-dive.